Drugs / [18F]CSB-321
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07057349 | Sep 2025 → Sep 2027 expected | metastatic malignant neoplasm | Cytosite Biopharma Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]CSB-321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07057349 ↗ |
| Modality | Diagnostic / imaging agent | “a PET imaging agent” NCT07057349 ↗ |